Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2019

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2019” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2019 10

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2019 10

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2019 12

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2019 13

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2019 14

2.4.1 Bristol-Myers Squibb to Acquire Celgene 14

2.4.2 Danaher to Acquire Biopharma Business from General Electric for USD21.4 Billion 16

2.4.3 Eli Lilly Acquires Loxo Oncology for USD8 Billion 16

2.4.4 Daiichi Sankyo Enters into Collaboration with AstraZeneca 17

2.4.5 Takeda Pharma Files Shelf Registration Statement for Public Offering of Hybrid Bonds Due 2079 for USD4.52 Billion 18

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 19

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2019 19

3.1.1 Top M&A Deals in Q1 2019 20

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2018 – Q1 2019 21

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2019 22

3.2.1 Top Initial Public Offerings in Q1 2019 23

3.2.2 Top Secondary Offerings in Q1 2019 23

3.2.3 Top PIPE Deals in Q1 2019 24

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2018 – Q1 2019 24

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2019 26

3.3.1 Top Venture Financing Deals in Q1 2019 27

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2019 28

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2019 29

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2018 – Q1 2019 30

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2018 – Q1 2019 31

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2018 – Q1 2019 32

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2019 33

3.4.1 Top Private Equity Deals in Q1 2019 34

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2018 – Q1 2019 34

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2019 36

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2019 36

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2018 – Q1 2019 38

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 39

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2019 40

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2019 40

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2019 41

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 42

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2018 – Q1 2019 44

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2018 – Q1 2019 45

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 46

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2019 48

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2019 48

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 49

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2019 50

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2019 50

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2019 51

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2018 – Q1 2019 52

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2018 – Q1 2019 53

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2018 – Q1 2019 55

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2018 – Q1 2019 56

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2018 – Q1 2019 57

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2019 59

6.1.1 Oncology – Deals of the Quarter 61

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2019 62

6.2.1 Central Nervous System – Deals of the Quarter 64

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2019 66

6.3.1 Infectious Disease – Deals of the Quarter 67

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2019 70

6.4.1 Immunology – Deals of the Quarter 72

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2019 73

6.5.1 Metabolic Disorders – Deals of the Quarter 74

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2019 76

6.6.1 Cardiovascular – Deals of the Quarter 78

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2019 79

6.7.1 Gastrointestinal – Deals of the Quarter 81

6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2019 82

6.8.1 Dermatology – Deals of the Quarter 83

6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2019 86

6.9.1 Respiratory – Deals of the Quarter 87

6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2019 89

6.10.1 Ophthalmology – Deals of the Quarter 90

7 Deal Summary by Geography 92

7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2019 92

7.1.1 North America – Deals of the Quarter 94

7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2019 95

7.2.1 Europe – Deals of the Quarter 96

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2019 98

7.3.1 Asia-Pacific – Deals of the Quarter 99

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2019 101

7.4.1 Rest of the World – Deals of the Quarter 102

8 Pharmaceuticals & Healthcare, Global, Top Advisors 104

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2018 – Q1 2019 104

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2018 – Q1 2019 105

9 Further Information 106

9.1 Methodology 106

9.2 About GlobalData 107

9.3 Contact Us 107

9.4 Disclosure information 107

9.5 Disclaimer 108

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 11

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2019 13

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2019 14

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 20

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2019 20

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2018 – Q1 2019 21

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 23

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2019 23

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2019 23

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2019 24

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 25

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 26

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2019 27

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2019 29

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 30

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 31

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2018 – Q1 2019 32

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 33

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2019 34

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 35

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 37

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 38

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 39

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2019 40

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2019 40

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2019 41

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2018 – Q1 2019 43

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2018 – Q1 2019 45

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2018 – Q1 2019 47

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 48

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 49

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2019 50

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2019 50

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2019 51

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 52

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2018 – Q1 2019 54

Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2018 – Q1 2019 56

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2018 – Q1 2019 58

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 60

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 63

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 67

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 71

Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 74

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 77

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 80

Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 83

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 87

Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 90

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 93

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 96

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 99

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 102

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 104

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 105

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2019 12

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2019 13

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 19

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2018 – Q1 2019 21

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 22

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q1 2018 – Q1 2019 24

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 26

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2019 28

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2019 29

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2018 – Q1 2019 30

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 31

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 33

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2018 – Q1 2019 34

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 36

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 38

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2018 – Q1 2019 39

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2018 – Q1 2019 42

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2018 – Q1 2019 44

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2018 – Q1 2019 45

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2018 – Q1 2019 46

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 48

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 49

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 52

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 53

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2018 – Q1 2019 55

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2018 – Q1 2019 56

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2018 – Q1 2019 57

Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 59

Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 62

Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 66

Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 70

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 73

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 76

Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 79

Figure 36: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 82

Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 86

Figure 38: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 89

Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 92

Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 95

Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 98

Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 101

Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 104

Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2018 – Q1 2019 105

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports